CatalYm is pioneering the neutralization of GDF-15 to overcome cancer therapy resistance, developing safe and efficacious immune therapies for solid tumors, particularly focusing on the lead antibody Visugromab
CatalYm is pioneering the neutralization of GDF-15 to overcome cancer therapy resistance, developing safe and efficacious immune therapies for solid tumors, particularly focusing on the lead antibody Visugromab.